$BMY 3 SEC Filings

Filed On	Filing
05 Aug 2025	Form 3: Massacesi Cristian, EVP,Chief Med Offr,Head of Dev No securities owned
16 Jun 2025	Form 3: Shibutani Hiroshi Chris, EVP, Chief Strategy Officer No securities owned
04 Jun 2025	Form 3: Short Bartie Wendy, EVP, Corporate Affairs
02 Jul 2024	Form 3: McMullen Michael R., Director No securities owned
04 Mar 2024	Form 3: Hickey Benjamin, President, RayzeBio Org. Holds 780 shares of Common Stock, $0.10 par value
23 Feb 2024	Form 3: Holzer Phil M, SVP and Controller Holds 10,011 shares of Common Stock, $0.10 par value
03 Jan 2024	Form 3: Poole Ahn Amanda, EVP, Chief Human Resources Holds 164.325 shares of Common Stock, $0.10 par value
20 Dec 2023	Form 3: Hoch Lynelle, President, Cell Therapy Org.
04 Oct 2023	Form 3: Gallman Cari, EVP, Corporate Affairs Holds 206 shares of Common Stock, $0.10 par value
05 Jul 2023	Form 3: Plenge Robert M, EVP, Chief Research Officer Holds 7,316 shares of Common Stock, $0.10 par value
03 May 2023	Form 3: Lenkowsky Adam, EVP, Chief Commercial Officer Holds 5,148.628 shares of Common Stock, $0.10 par value
16 Jun 2022	Form 3: Bhatt Deepak, Director No securities owned
04 May 2022	Form 3: Greenlees Sharon, SVP & Controller No securities owned
15 Mar 2022	Form 3: Shanahan Karin, EVP, Glob. Prod. Dev. & Supply No securities owned
03 Feb 2022	Form 3: Meyers Gregory Scott, EVP, Chief Digital & Tech Off. No securities owned
15 Jun 2021	Form 3: Weese Michelle, EVP, Corporate Affairs No securities owned
03 Jun 2021	Form 3: Hidalgo Medina Manuel, Director No securities owned
08 Sep 2020	Form 3: Price Paula A, Director No securities owned
08 Sep 2020	Form 3: Rice Derica W, Director Holds 1,200 shares of Common Stock, $0.10 par value
06 Jul 2020	Form 3: Bristol Myers Squibb Co, 10% owner · ACCELERON PHARMA INC Holds 6,971,772 shares of Common Stock

Comments